Related Experiment Video
Updated: Jun 25, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Raltegravir and etravirine are active against HIV type 1 group O
Verónica Briz1, Carolina Garrido, Eva Poveda
1Department of Infectious Disease, Hospital Carlos III, Madrid, Spain. veronica.briz@terra.es
Abstract:
Abstract The activity of raltegravir and etravirine was assessed in vitro in HIV-1 group O isolates. Despite the presence of some natural polymorphisms associated with resistance to raltegravir (V72I, L74I, S153A, V201I, and T206S) and etravirine (G190A), both drugs showed significant antiviral activity. Subsequently, the clinical benefit was shown in an HIV-1 group O-infected individual in whom enfuvirtide was replaced by raltegravir. Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly

